Finoriq research workspace
NEUROCRINE BIOSCIENCES INC (NBIX) SEC Filings & Filing Highlights
Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for. Review NBIX SEC filings, filing highlights, and disclosure activity on Finoriq.
Company Snapshot
Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia, as well as offers products under the name of ALKINDI and Efmody. Its product candidates in clinical development includes NBI-1076986 to treat movement disorders; Osavampator for inadequate response to treatment in major depressive disorder; NBI-1117568 for the treatment of schizophrenia and bipolar mania; NBI-1117567 for the treatment of Alzheimer's disease; NBI 921355 for the treatment of epilepsy; NBIP-01435 for the treatment of congenital adrenal hyperplasia; NBIP-2118 for the treatment of obesity and related metabolic diseases; and NBI-1070770 to treat major depressive disorder; and NBI-1117570, NBI-1117567, NBI-1117569, NBI-1140675, and NBI-1065890 for neuropsychiatric and neurological conditions. The company also has license and collaboration agreements with Nxera Pharma UK Limited; Takeda Pharmaceutical Company Limited; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; Sanofi S.A.; Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.
- Company
- NEUROCRINE BIOSCIENCES INC (NBIX)
- Ticker
- NBIX
- Market Cap
- $17.5B
- Latest Price
- $174.01
- Industry
- Biotech & Pharma
NEUROCRINE BIOSCIENCES INC (NBIX) Recent SEC Filing Highlights
Recent SEC filings, filing events, and disclosure highlights indexed for NEUROCRINE BIOSCIENCES INC (NBIX).
| Event | Form | Date |
|---|---|---|
| •Election of three Class III Directors for a term of three years expiring at the 2029 Annual Me...On May 27, 2026, the Company held its Annual Meeting. As of the close of business on March 31, 2026, the record date for the Annual Meeting... | 8-K5.07 | 2026-05-28 |
| (e) As discussed below in Item 5.07, Neurocrine Biosciences, Inc. (the “Company”) held its 2026...(e) As discussed below in Item 5.07, Neurocrine Biosciences, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual... | 8-K5.02 | 2026-05-28 |
| Neurocrine Biosciences Completes Acquisition of Soleno TherapeuticsNeurocrine Biosciences Completes Acquisition of Soleno Therapeutics | 8-K7.01 | 2026-05-18 |
| Debt or FinancingDebt or Financing | 8-K2.03 | 2026-05-18 |
| NEUROCRINE BIOSCIENCES INC: Acquisition or asset dispositionThe Offer and related withdrawal rights expired as scheduled at one minute following 11:59 p.m. Eastern time on May 15, 2026 (such date and... | 8-K2.01 | 2026-05-18 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.